Effects of sulfasalazine on selected lymphocyte subpopulations in vivo and in vitro

Digestive Diseases and Sciences
W R ThayerC E Field

Abstract

Sulfasalazine has proven to be an effective agent in the therapy of inflammatory bowel disease (IBD). Despite long and widespread usage, the mechanism of action of this drug is still not understood. Several investigators have suggested that the drug might act as an immunosuppressant. To examine this possibility, an in vivo study was undertaken to ascertain any quantitative change in the circulating T cells, Ig-bearing B cells, and complement receptor-bearing lymphocytes (CRL) of patients before and during therapy with sulfaslazine. Concomitant responses to skin test antigens were also evaluated. In vitro studies with control cells were performed to determine the influence of sulfasalazine and its components (sulfapyridine or 5-aminosalicylic acid) on the extent of antibody-dependent cellular cytotoxicity (ADCC), as well as on the number of T cells and CRL. Results indicate that neither sulfasalazine nor either of its components quantitatively alters those subpopulations of circulating mononuclear cells studied in vivo or in vitro--nor are these compounds responsible for any functional inhibition of ADCC.

References

Feb 1, 1985·Digestive Diseases and Sciences·H MiyazakiC Hirayama
Dec 1, 1987·Clinical Rheumatology·N FelteliusO Sjöberg
Aug 1, 1994·Pharmacology & Therapeutics·S P Travis, D P Jewell
Jan 1, 1992·Mediators of Inflammation·N A PunchardR P Thompson
May 8, 2002·Paediatric Drugs·Ian C Chikanza
Apr 1, 1987·Journal of Clinical Pharmacology·M A Peppercorn

Citations

Sep 20, 1976·Clinica Chimica Acta; International Journal of Clinical Chemistry·A KahnP Boivin
Apr 1, 1978·The American Journal of Digestive Diseases·W R ThayerC E Field
Sep 1, 1975·Cellular Immunology·A V MuchmoreR M Blaese
Jul 6, 1974·Lancet·K RamachandarR N Taub
Jul 1, 1972·Clinical Pharmacology and Therapeutics·H Schröder, D E Campbell
Apr 1, 1974·Clinical Immunology and Immunopathology·D T YuK M Nies
Sep 1, 1970·Cellular Immunology·P Perlmann, H Perlmann
Jan 1, 1962·Proceedings of the Society for Experimental Biology and Medicine·C MARTINEZR A GOOD
Sep 30, 1961·Lancet·J F MILLER

Related Concepts

T-Lymphocyte
Mononuclear Cells
Lymphocytes as Percentage of Blood Leukocytes (Lab Test)
Lymphoid Cells
Sulfasalazin medac
Differential White Blood Cell Count Procedure
IgG2B
Complement Receptor
B-Lymphocytes
Complement Receptor Type 1

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.